84 related articles for article (PubMed ID: 16874019)
1. Links between biology, prognosis and prediction of response to chemotherapy in colorectal cancer.
Mader RM
Onkologie; 2006 Jul; 29(7):334-41. PubMed ID: 16874019
[TBL] [Abstract][Full Text] [Related]
2. Prognostic biomarkers in resected colorectal cancer: implications for adjuvant chemotherapy.
Graziano F; Catalano V; Baldelli AM; Cascinu S
Expert Rev Anticancer Ther; 2001 Aug; 1(2):247-57. PubMed ID: 12113030
[TBL] [Abstract][Full Text] [Related]
3. Molecular markers in prognosis of colorectal cancer and prediction of response to treatment.
Pasche B; Mulcahy M; Benson AB
Best Pract Res Clin Gastroenterol; 2002 Apr; 16(2):331-45. PubMed ID: 11969242
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomics and -genetics in colorectal cancer.
Pohl A; Lurje G; Manegold PC; Lenz HJ
Adv Drug Deliv Rev; 2009 May; 61(5):375-80. PubMed ID: 19100300
[TBL] [Abstract][Full Text] [Related]
5. Tumor cell-microenvironment interaction models coupled with clinical validation reveal CCL2 and SNCG as two predictors of colorectal cancer hepatic metastasis.
Hu H; Sun L; Guo C; Liu Q; Zhou Z; Peng L; Pan J; Yu L; Lou J; Yang Z; Zhao P; Ran Y
Clin Cancer Res; 2009 Sep; 15(17):5485-93. PubMed ID: 19706805
[TBL] [Abstract][Full Text] [Related]
6. Telomerase activity--a prognostic factor in colorectal cancer?
Brümmendorf TH
Onkologie; 2005 Nov; 28(11):550-1. PubMed ID: 16249639
[No Abstract] [Full Text] [Related]
7. Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer.
Zlobec I; Minoo P; Baumhoer D; Baker K; Terracciano L; Jass JR; Lugli A
Cancer; 2008 Feb; 112(3):495-502. PubMed ID: 18076013
[TBL] [Abstract][Full Text] [Related]
8. Molecular markers in the treatment of metastatic colorectal cancer.
Wilson PM; Labonte MJ; Lenz HJ
Cancer J; 2010; 16(3):262-72. PubMed ID: 20526105
[TBL] [Abstract][Full Text] [Related]
9. [Biomarker for chemotherapy in patients with colorectal cancer].
Matsusaka S
Gan To Kagaku Ryoho; 2009 Jan; 36(1):11-4. PubMed ID: 19151559
[TBL] [Abstract][Full Text] [Related]
10. Expression of p16 in lymph node metastases of adjuvantly treated stage III colorectal cancer patients identifies poor prognostic subgroups: a retrospective analysis of biomarkers in matched primary tumor and lymph node metastases.
Karamitopoulou E; Zlobec I; Koumarianou A; Patsouris ES; Peros G; Lugli A
Cancer; 2010 Oct; 116(19):4474-86. PubMed ID: 20572035
[TBL] [Abstract][Full Text] [Related]
11. Analysis of apoptosis protein expression in early-stage colorectal cancer suggests opportunities for new prognostic biomarkers.
Krajewska M; Kim H; Kim C; Kang H; Welsh K; Matsuzawa S; Tsukamoto M; Thomas RG; Assa-Munt N; Piao Z; Suzuki K; Perucho M; Krajewski S; Reed JC
Clin Cancer Res; 2005 Aug; 11(15):5451-61. PubMed ID: 16061861
[TBL] [Abstract][Full Text] [Related]
12. Detection of disseminated tumour cells as a potential surrogate-marker for monitoring palliative chemotherapy in colorectal cancer patients.
Staritz P; Kienle P; Koch M; Benner A; von Knebel Doeberitz M; Rudi J; Weitz J
J Exp Clin Cancer Res; 2004 Dec; 23(4):633-9. PubMed ID: 15743034
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and predictive factors in colorectal cancer.
Zlobec I; Lugli A
J Clin Pathol; 2008 May; 61(5):561-9. PubMed ID: 18326017
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiles as an additional tool to conventional predictive factors to assist in management of early endocrine responsive breast cancer.
Chow LW
Expert Opin Investig Drugs; 2010 Apr; 19 Suppl 1():S13-7. PubMed ID: 20374025
[TBL] [Abstract][Full Text] [Related]
15. Biomolecular markers as determinants of patients selection for adjuvant chemotherapy of sporadic colorectal cancers.
Sudoyo AW
Acta Med Indones; 2010 Jan; 42(1):45-50. PubMed ID: 20737746
[TBL] [Abstract][Full Text] [Related]
16. SMAD4 levels and response to 5-fluorouracil in colorectal cancer.
Alhopuro P; Alazzouzi H; Sammalkorpi H; Dávalos V; Salovaara R; Hemminki A; Järvinen H; Mecklin JP; Schwartz S; Aaltonen LA; Arango D
Clin Cancer Res; 2005 Sep; 11(17):6311-6. PubMed ID: 16144935
[TBL] [Abstract][Full Text] [Related]
17. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features.
Ioachim E
Int J Clin Pract; 2008 Nov; 62(11):1736-43. PubMed ID: 19143860
[TBL] [Abstract][Full Text] [Related]
18. Development of molecular biomarkers in individualized treatment of colorectal cancer.
De Mattos-Arruda L; Dienstmann R; Tabernero J
Clin Colorectal Cancer; 2011 Dec; 10(4):279-89. PubMed ID: 21729679
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers and targeted therapeutics in colorectal cancer.
Meguerditchian AN; Bullard Dunn K
Surg Oncol Clin N Am; 2013 Oct; 22(4):841-55. PubMed ID: 24012402
[TBL] [Abstract][Full Text] [Related]
20. What is the role and impact of molecular markers on treatment decisions for colorectal cancer in the adjuvant setting?
Al-Salama HM; Johnstone EC; Kerr DJ
Discov Med; 2009 Oct; 8(42):104-7. PubMed ID: 19833054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
